秋水仙碱与他汀类药物联用的真实世界安全性
倾向评分匹配后共31,839人,结果显示联合治疗组CK升高>3×ULN(HR 1.74)和临床诊断肌病(HR 1.50)风险最高,但超出他汀单药治疗的额外风险较小,支持临床需要时联用。
要点
- 联合治疗组CK>3×ULN风险高于无治疗(HR 1.74),但比他汀单药(HR 1.64)仅略高。
- 单用秋水仙碱未显著增加CK>3×ULN风险(HR 1.08,95%CI 0.89-1.31)。
- 临床诊断肌病少见,联合治疗组风险最高(HR 1.50),但额外风险小。
核心结论
- 秋水仙碱与他汀联用与更高的实验室和临床不良事件率相关,但超出他汀单药治疗的额外风险较小,支持临床需要时联用。
主要发现
- 与无治疗相比,CK升高>3×ULN见于他汀单药(HR 1.64,95%CI 1.39-1.93)和联合治疗(HR 1.74,95%CI 1.44-2.09),但不见于单用秋水仙碱(HR 1.08,95%CI 0.89-1.31)。
- 临床诊断肌病少见,风险呈暴露组梯度增加,联合治疗组最高(HR 1.50,95%CI 1.31-1.72)。
临床怎么用
- 临床需要时可按指征联用秋水仙碱与他汀,但应关注CK升高和肌病风险,尤其联合治疗组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the risk of clinically meaningful muscle- and liver-related outcomes associated with concomitant colchicine-statin therapy in a real-world setting, and to determine whether concomitant therapy increases the incidence of toxicity compared with either agent alone. METHODS: This was a retrospective cohort study using the national Clalit Health Services database (≈5.4 million insured individuals). Adults with gout or familial Mediterranean fever between 2010 and 2024 were categorized into four exposure groups: no treatment, colchicine only, statin only, or concomitant therapy. Propensity-score matching was used to balance baseline characteristics. The primary outcome was creatine kinase (CK) elevation >3× the upper limit of normal (ULN), and secondary outcomes included alanine transaminase elevation >5× the ULN, myopathy, liver disease, and hospitalizations related to these conditions. RESULTS: Eligible participants before and after propensity-score matching were 104,066 and 31,839, respectively (no treatment n = 7,146; colchicine only n = 7,146; statin only n = 9,030; concomitant therapy n = 8,517). Compared with no treatment, CK elevations >3× ULN were observed with statin therapy (hazard ratio [HR] 1.64 [95% confidence interval (CI) 1.39-1.93]) and concomitant colchicine-statin therapy (HR 1.74 [95% CI 1.44-2.09]) but not with colchicine therapy alone (HR 1.08 [95% CI 0.89-1.31]). Clinically diagnosed myopathy was infrequent and showed a graded increase across exposure groups, with the highest risk observed in the concomitant treatment group (HR 1.50 [95% CI 1.31-1.72]). CONCLUSION: Although colchicine-statin concomitant therapy was associated with higher rates of laboratory and clinical adverse events, the additional risk beyond statin monotherapy was small, supporting their use when clinically indicated.
引用
- Meidan R, Loutati R, Caspi D, et al. Real-World Safety of Concomitant Colchicine and Statin Therapy. Arthritis Care Res (Hoboken). 2026. PMID: 42803209. doi:10.1002/acr.80172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。